Viral load refers to the amount of viral genetic material, typically RNA or DNA, present in a given volume of a patient's blood or other biological samples. Measured using quantitative polymerase chain reaction (PCR) or similar techniques, it provides a quantitative assessment of the extent of viral replication within an individual. In the context of infections like HIV, hepatitis, and COVID-19, monitoring viral load is crucial for assessing disease progression, treatment efficacy, and transmission risk. Higher viral loads often correlate with increased disease severity and a greater potential for transmission to others. Viral load testing is a key component of managing viral infections, guiding treatment decisions, and determining when interventions such as antiretroviral therapy should be initiated or adjusted. Undetectable or low viral loads are often associated with better clinical outcomes and reduced transmission risk. Regular viral load monitoring plays a pivotal role in personalized medicine, enabling healthcare providers to tailor treatment plans based on an individual's specific viral dynamics and response to therapy.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe